Glycopyrrolate/indacaterol - Novartis

Drug Profile

Glycopyrrolate/indacaterol - Novartis

Alternative Names: Indacaterol maleate/glycopyrronium bromide; Indacaterol/glycopyrrolate; Indacaterol/NVA-237; NVA-237/indacaterol; NVA-237/QAB-149; QVA-149; Ultibro Breezhaler; Ultibro Inhalation Capsules; Ulunar Breezhaler; Utibron Neohaler; Xoterna Breezhaler

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Arakis Ltd; Novartis; Vectura
  • Developer Novartis; Pfizer; Sunovion Pharmaceuticals
  • Class Antiasthmatics; Antispasmodics; Bronchodilators; Indans; Pyrrolidines; Quaternary ammonium compounds; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 11 Jun 2018 Novartis initiates enrolment in a phase III trial for Chronic obstructive pulmonary disease in Netherlands (EudraCT2017-001593-42)
  • 18 May 2018 Pooled efficacy data from a two phase III trials (FLIGHT1 and FLIGHT2) in Chronic obstructive pulmonary disease presented at at the 114th International Conference of the American Thoracic Society (ATS-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top